---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-065185"
form_type: "8-K"
ticker: null
cik: "0001832415"
company_name: "Better Therapeutics, Inc."
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:29:49.177112+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Better Therapeutics CFO Mark Heinen resigns; CEO Frank Karbe takes over as principal financial officer

## Summary
- CFO Mark Heinen resigned effective Nov 27, 2023, as part of expense reduction measures.
- CEO Frank Karbe assumes principal financial officer duties; controller Leslie Miller becomes principal accounting officer.
- Miller receives a base salary increase and annual incentive compensation upon appointment.
- Measures include voluntary salary reductions by CEO and other executives to extend cash runway for AspyreRx.
- Resignation not due to any disagreement with the company.

## SEC filing metadata
- accession: 0000950170-23-065185
- form_type: 8-K
- cik: 0001832415
- company_name: Better Therapeutics, Inc.
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/0000950170-23-065185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/bttx-20231117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-065185
- JSON: https://secwatch.observer/filing/0000950170-23-065185.json
- Plain text: https://secwatch.observer/filing/0000950170-23-065185.txt

## Key facts
- Executive change
  Mark Heinen resigned as Chief Financial Officer at Better Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On November 14, 2023, Mark Heinen notified Better Therapeutics, Inc. (the “Company”) of his resignation as the chief financial officer of the Company, effective November 27, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/0000950170-23-065185-index.htm
- Executive change
  Frank Karbe was appointed as Principal Financial Officer at Better Therapeutics, Inc..
  - Action: appointed
  - Role: Principal Financial Officer
  source text: Frank Karbe, the Company's chief executive officer ("CEO"), will assume the duties of principal financial officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/0000950170-23-065185-index.htm
- Executive change
  Leslie Miller was appointed as Principal Accounting Officer at Better Therapeutics, Inc..
  - Action: appointed
  - Role: Principal Accounting Officer
  source text: Leslie Miller, the Company's controller, will assume the duties of principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/0000950170-23-065185-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.